5 completed, 3 recruiting, 1 unknown. 9 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Recruiting 3, Unknown 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy Educational Intervention, Health Telemonitoring, Questionnaire Administration - Hematologic Malignancies | Phase 3 | Recruiting | City of Hope Medical Center | 380 | 2026-01-14 | 2026-08-28 |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) ICP-248, Orelabrutinib - Hematologic Malignancies | Phase 2 / Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 226 | 2024-05-15 | 2025-11-21 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Pembrolizumab, Standard of Care (SOC), Lenvatinib - Solid Tumors, Hematologic Malignancies | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 3500 | 2018-08-21 | 2026-10-29 |
| Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Denosumab, Zoledronic acid, Placebo to Denosumab - Cancer, Hematologic Malignancies | Phase 3 | Completed | Amgen | 1718 | 2012-05-17 | 2022-11-08 |
| Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Red blood cell Transfusion - Hematologic Malignancies | Phase 3 | Completed | Ottawa Hospital Research Institute | 300 | 2011-03-01 | 2016-10-12 |
| Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin) - Hematologic Malignancies | Phase 3 | Unknown | McMaster University | 198 | 2010-04-01 | 2010-10-08 |
| Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Posaconazole, ABLC - Invasive Fungal Infections, Hematologic Malignancies | Phase 3 | Completed | M.D. Anderson Cancer Center | 46 | 2008-06-01 | 2016-09-29 |
| Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy StemEx® - Hematologic Malignancies, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Completed | Gamida Cell -Teva Joint Venture Ltd. | 101 | 2007-10-01 | 2015-07-10 |
| Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation Empirical Vancomycin, Prophylactic Vancomycin - Streptococcal Sepsis, Hematologic Malignancies | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 126 | 2003-11-01 | 2006-09-08 |
Hematologic Neoplasms (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Myelodysplastic Syndromes (2) · Blood Protein Disorders (1) · Bone Diseases (1) · Bone Marrow Diseases (1) · Bone Neoplasms (1) · Fractures, Bone (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Invasive Fungal Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1)
Hemic and Lymphatic Diseases (9) · Neoplasms by Site (9) · Hematologic Diseases (8) · Neoplasms (8) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms by Histologic Type (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bone Marrow Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Leukemia (2) · Leukemia, Myeloid (2)
Standard of Care (2) · Amphotericin B (1) · Antilymphocyte Serum (1) · Denosumab (1) · Early Intervention, Educational (1) · Educational Status (1) · Erythrocyte Transfusion (1) · Methods (1) · Practice Guidelines as Topic (1) · Zoledronic Acid (1) · lenvatinib (1) · olaparib (1) · orelabrutinib (1) · pembrolizumab (1) · posaconazole (1)
Amgen (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · City of Hope Medical Center (1) · Gamida Cell -Teva Joint Venture Ltd. (1) · M.D. Anderson Cancer Center (1) · McMaster University (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Ottawa Hospital Research Institute (1)
United States (6) · Canada (4) · Hungary (3) · Italy (3) · Spain (3) · Australia (2) · Austria (2) · China (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Hong Kong (2) · Ireland (2) · Israel (2)
Agha Mounzer, MD (1) · Alberto Bosi, MD (1) · Celia Grosskreutz, MD (1) · Christelle Ferra, MD (1) · Cristina Arbona, MD (1) · Dr. Cristina Diaz de Heredia, MD (1) · Dr. Mi Kwon, MD (1) · Dr. Pere Barba, MD (1) · Entezam Sahovic, MD (1) · Guillermo Sanz, MD (1) · Igor B. Resnick, MD, PhD (1) · Irwin Walker, MD (1) · Issam Raad, MD/Professor (1) · Jason Tay, MD FRCPC MSc (1) · Jorge Sierra, MD (1)
PMID 22814329, PMID 29477778, PMID 31756535, PMID 31958417, PMID 32083994, PMID 34932836, PMID 37341189, PMID 37348035, PMID 39306585, PMID 41114449
2017 (1)